Sign up USA
Proactive Investors - Run By Investors For Investors

Immune Pharmaceuticals surges as Ceplene is set for Latin American roll-out

Immune has entered into a letter of intent with Pint Pharma GmnH, which is focused on Latin America and other markets.
Immune Pharmaceuticals surges as Ceplene is set for Latin American roll-out
Pint will also invest $4mln into Immune Pharma's oncology subsidiary Cytovia

Immune Pharmaceuticals Inc (NASDAQ: IMNP) shares surged 48% to $3.61 on the day as it struck a deal to commercialize Ceplene throughout Latin America.

Ceplene is administered in conjunction with low dose interleukin-2 (IL-2), for maintenance of first remission in patients with Acute Myeloid Leukemia (AML).

Immune has entered into a letter of intent with Pint Pharma GmnH, which is focused on Latin America and other markets.

Pint will be responsible for registration of Ceplene in Latin American countries based on the existing European marketing authorization and will carry out the full commercialization of the licensed product.

Pint will also invest $4mln into Immune Pharma's oncology subsidiary Cytovia Inc.

"We are excited about the possibility of partnering with Pint Pharma, a market leader in Latin America with strong commercialization capabilities in the field of oncology.

"Pint Pharma's desire to bring Ceplene/IL-2 immunotherapy to patients in Latin America  complements our strategy," said Dr Daniel Teper, chief executive of Immune.

According to Pint, there are around 10,000 new cases of AML diagnosed per year in Latin America and there is currently no approved treatment for the maintenance of  AML remission.

Giles_55af4ddca6481.jpg


Register here to be notified of future IMNP Company articles
View full IMNP profile View Profile

Immune Pharmaceuticals Timeline

Related Articles

picture of drug lab
February 07 2017
Amryt Pharma’s strategy to acquire, in-license and then develop drugs for hard to treat, so-called orphan diseases has been seeing some good progress.
GW_Pharma.png
June 07 2017
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use